First Time Loading...
N

NewAmsterdam Pharma Company NV
NASDAQ:NAMS

Watchlist Manager
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
Watchlist
Price: 19.41 USD 3.13% Market Closed
Updated: May 29, 2024
Section:
 

Relative Value

The Relative Value of one NAMS stock under the Base Case scenario is 0.33 USD. Compared to the current market price of 19.41 USD, NewAmsterdam Pharma Company NV is Overvalued by 98%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NAMS Relative Value
Base Case
0.33 USD
Overvaluation 98%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

13.7
P/S
P/S
Price to Sales
13.7
vs History
9
vs Industry
39
Median 3Y
0
Median 5Y
0
Industry
8
Forward
206.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
0
Median 3Y
-13.4
Median 5Y
-14
Industry
26.3
Forward
-8.6
More Details
184.3
P/OCF
P/OCF
Price to OCF
184.3
vs History
9
vs Industry
1
Median 3Y
-243.2
Median 5Y
-252
Industry
23.9
More Details
192.5
P/FCFE
P/FCFE
Price to FCFE
192.5
vs History
9
vs Industry
1
Median 3Y
-243.2
Median 5Y
-252
Industry
23.2
More Details
3.5
P/B
P/B
Price to Book Value
3.5
vs History
9
vs Industry
28
Median 3Y
1.4
Median 5Y
1.4
Industry
2.5
More Details
10.1
EV/S
EV/S
Enterprise Value to Sales
10.1
vs History
9
vs Industry
38
Median 3Y
0
Median 5Y
0
Industry
7.1
Forward
152.7
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.6
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-133.4
Median 5Y
-143.8
Industry
4.8
Forward
-4.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-131
Median 5Y
-141.2
Industry
4.7
Forward
-8.2
More Details
136.2
EV/OCF
EV/OCF
Enterprise Value to OCF
136.2
vs History
9
vs Industry
1
Median 3Y
-242.3
Median 5Y
-251.1
Industry
6.3
More Details
136.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
136.4
vs History
9
vs Industry
1
Median 3Y
-242.3
Median 5Y
-251.1
Industry
3.9
More Details
16.3
EV/IC
EV/IC
Enterprise Value to IC
16.3
vs History
9
vs Industry
15
Median 3Y
1.3
Median 5Y
1.3
Industry
4.6
More Details

Multiples Across Competitors

NAMS Competitors Multiples
NewAmsterdam Pharma Company NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NL
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
1.6B USD 13.7 -9.3 -7.4 -7.4
US
Abbvie Inc
NYSE:ABBV
274.3B USD 5 46.1 13 20
US
Amgen Inc
NASDAQ:AMGN
161B USD 5.5 42.8 18.2 30
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD 11.3 28.7 24.1 25.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
107.2B USD 8.2 27.8 22.5 24.9
AU
CSL Ltd
ASX:CSL
135.6B AUD 6.4 36.5 22 27.3
US
Gilead Sciences Inc
NASDAQ:GILD
79.7B USD 2.9 164.6 8.4 11
US
Moderna Inc
NASDAQ:MRNA
58.7B USD 11.4 -9.8 -11.1 -9.9
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
31.8B USD 3.3 27.3 14 17.5
KR
Celltrion Inc
KRX:068270
36.9T KRW 15.9 93.9 47.3 79

See Also

Summary
NAMS intrinsic value, competitors valuation, and company profile.
DCF Valuation
NAMS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NAMS stock valuation using valuation multiples.
Wall Street Estimates
NAMS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NAMS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 141,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.